research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
Search
for
Sort by
Research
180-210 / 1000+ results research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Breast cancer treatments work better with AR activation, improving results and reducing side effects.
research Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
EGFR-targeting cancer drugs can cause skin rashes and other side effects.
research Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
Erlotinib can cause scalp pustules and hair loss, needing early treatment with antibiotics and steroids.
research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
research Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
research “PRIDE” Complex
Certain cancer drugs can cause skin issues like rashes and itching.
research Tebentafusp-tebn (Kimmtra®)
Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
research A Case of Hair Change and Acneiform Eruption Induced by ZD1839 (Iressa$^{(R)}$)
ZD1839 can cause skin issues like acne and hair changes.
research Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
research Loose anchoring of anagen hairs and pili torti due to erlotinib
Erlotinib can cause hair loss and texture changes.
research Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
research Alopecia Universalis: Never Give Up?
Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
research Tofacitinib in the Management of Alopecia Universalis
Tofacitinib helped a woman regrow hair with no major side effects.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
research Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Gefitinib: an adverse effects profile
Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
research The PDGF/PDGFR pathway as a drug target
The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
research In‐silico Screening of ATP‐competitive Inhibitory Activities of Phytochemicals against Janus Kinase 3 and Its In‐vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Bexxar, iodine I 131 tositumomab, Effective in Long Term Follow-up of Non-Hodgkin's Lymphoma
Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Folliculitis decalvans associated with erlotinib
Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
research Sorafenib-induced eruption resembling pityriasis rubra pilaris
A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.